Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and tolerability of escalating multiple doses of ORM-12741 in healthy volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ORM-12741 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ORM-12741 | Drug | Alternating panel multiple dose escalation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values | about a month |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics | 12 days per period |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Déborah Metzger, Medical Doctor | Forenap Pharma | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Forenap Pharma | Rouffach | France |
Not provided
| ID | Term |
|---|---|
| C000588919 | ORM-12741 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided